Browsing by Author Chaiyut Charoentum

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 7 of 7
Issue DateTitleAuthor(s)
1-Dec-2011Cost-effectiveness analysis of cisplatin plus etoposide and carboplatin plus paclitaxel in a phase III randomized trial for non-small cell lung cancerSumitra Thongprasert; Unchalee Permsuwan; Chidchanok Ruengorn; Chaiyut Charoentum; Busyamas Chewaskulyong
1-Oct-2007Phase II study of 24-hour infusion of paclitaxel (Intaxel) with carboplatin in advanced non-small cell lung cancer.Chaiyut Charoentum; Sumitra Thongprasert; Busayamas Chewasakulyong
1-Nov-2007Phase II study of cisplatin combined to irinotecan administered alternatingly with docetaxel in advanced non-small cell lung cancerChaiyut Charoentum; Sumitra Thongprasert; Busayamas Chewasakulyong; Juntima Euathrongchit; Sirikul Sorraritchingchai; Sutthirak Munprakan
1-Feb-2006A phase II study of docetaxel and carboplatin in Thai patients with advanced non-small-cell lung cancerSumitra Thongprasert; Sirikul Soorraritchingchai; Busayamas Chewaskulyong; Chaiyut Charoentum; Sutthirak Munprakan
30-Mar-2020Phase II, multi-center, open-label, single-arm clinical trial evaluating the efficacy and safety of Mycophenolate Mofetil in patients with high-grade locally advanced or metastatic osteosarcoma (ESMMO): Rationale and design of the ESMMO trialNut Koonrungsesomboon; Nuttapong Ngamphaiboon; Natavudh Townamchai; Pimpisa Teeyakasem; Chaiyut Charoentum; Pimlak Charoenkwan; Rungrote Natesirinilkul; Lalita Sathitsamitphong; Touch Ativitavas; Parunya Chaiyawat; Jeerawan Klangjorhor; Suradej Hongeng; Dumnoensun Pruksakorn
1-Jan-2019Stage-specific survival rate of breast cancer patients in Northern Thailand in accordance with two different staging systemsImjai Chitapanarux; Patumrat Sripan; Areewan Somwangprasert; Chaiyut Charoentum; Wimrak Onchan; Kirati Watcharachan; Panchaporn Wongmaneerung; Pailin Kongmebhol; Bongkot Jia-Mahasap; Lalita Huntrakul
21-Jul-2006Thai female non-smoker with recurrent lung adenocarcinoma who has dramatic and prolonged response to gefitinib for over one yearChaiyut Charoentum